Respiratory Syncytial Virus Infection
📧 Sign up to get email alerts when something new happens for Respiratory Syncytial Virus Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers [Phase 2]
Phase 2 clinical trial update for Moderna's mRNA-1345 RSV vaccine given to pregnant women and infants of vaccinated mothers; the study is ac…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
Pfizer's RSV vaccine Abrysvo is being studied in adults aged 60 and older, and the trial is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants
This clinical trial update reports the real-world effectiveness of nirsevimab against respiratory syncytial virus–related infections and all…
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers [Phase 3]
Phase 3 study evaluating the immunogenicity and safety of three RSV vaccine dose concentrations in infants and toddlers; the trial has been …
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
This ClinicalTrials.gov update reports on the effectiveness of Pfizer's ABRYSVO maternal RSV vaccine in preventing RSV in infants in Western…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers [Phase 3]
A phase 3 trial evaluating the efficacy, immunogenicity, and safety of Sanofi Pasteur's RSV vaccine in infants and toddlers has been termina…
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers [Phase 3]
A Phase 3 trial evaluating co-administration of an investigational live-attenuated Respiratory Syncytial Virus vaccine in infants and toddle…
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age [Phase 3]
Phase 3 trial examining mRNA-1345 given after a licensed protein subunit RSV vaccine in adults aged 60 and older; study status is Active Not…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. [Phase 3]
Pfizer's Phase 3 study evaluating the RSVpreF vaccine for efficacy, immunogenicity, and safety in adults with lower respiratory tract illnes…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA) [Phase 1, Phase 2]
Phase 1/2 trial of a live-attenuated RSV vaccine by Sanofi Pasteur to evaluate safety, transmissibility, and genetic stability of the vaccin…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus [NA]
A trial evaluating how age affects adaptive immunity in adults infected with respiratory syncytial virus. The study has completed and result…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants [Phase 1, Phase 2]
Phase Ib/IIa trial evaluating SIBP-A16 Injection in premature and full-term infants for respiratory syncytial virus infection; the study is …
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Systems Biological Analysis of Immune Responses to RSV Vaccine [Phase 4]
A Phase 4 clinical trial is studying systems biological analyses of immune responses to an RSV vaccine, with the study currently ACTIVE_NOT_…
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. [Phase 1]
Sanofi completed a Phase 1 clinical trial evaluating the safety and immunogenicity of vaccines targeting influenza, respiratory syncytial vi…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: RSV-Positive Children <5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSV
The TRUST-RSV trial in Türkiye is studying RSV-positive children under 5 presenting to pediatric emergency departments, and the study is cur…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing [NA]
A clinical trial evaluating whether using a triplex rapid diagnostic test for SARS-CoV-2, influenza, and RSV changes antibiotic prescribing …
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Covid Flu A/B and RSV 4 in 1 Diagnostic Test
Clinical trial update on a 4-in-1 diagnostic test for detecting Influenza A, Influenza B, COVID-19, and RSV, sponsored by iHealth Labs Inc.,…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: RSV Burden in Hong Kong
A clinical trial led by The Chinese University of Hong Kong is studying the burden of respiratory syncytial virus (RSV) in Hong Kong and is …
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: COVID-19 Impact on RSV Emergency Presentations
A recruiting clinical trial studying the impact of COVID-19 on emergency presentations for bronchiolitis associated with Respiratory Syncyti…
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age [Phase 3]
Phase 3 results for Moderna's RSV vaccine candidate mRNA-1345 in adults aged 50 and older have been posted after study completion.
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV [Phase 1]
Phase 1 study of Sisunatovir in infants and children with pneumonia due to respiratory syncytial virus was terminated; results have been pos…
-
CLINICAL_TRIALS trial_result · 2025-12-26Clinical Trial Update: A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) [Phase 3]
Phase 3 study assessing immune response and safety of the RSV vaccine Arexvy in adults aged 50-59 at increased risk and 60 years and older; …
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients [Phase 4]
Phase 4 trial update assessing immune response to an RSV vaccine in recipients of stem cell transplantation and CAR-T therapy, currently not…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults [Phase 1]
Phase 1 clinical trial update for VXB-251, a trivalent vaccine targeting RSV, human metapneumovirus, and parainfluenza virus type 3, studied…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants
Pfizer's ABRYSVO maternal RSV vaccine is listed as active but not recruiting in a trial evaluating infant effectiveness.